Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers
Launched by COORDINACIÓN DE INVESTIGACIÓN EN SALUD, MEXICO · Aug 31, 2020
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
In a blinded randomized clinical trial, which will include health workers (doctors, residents, nurses, stretcher-bearers, technicians, hygiene and cleaning) who are members of the health teams that care for patients with COVID-19. Participants with a history of having COVID-19 disease or who are consuming vitamin D at that time will be excluded. Through randomization, two groups will be formed: the Vitamin D group taking 4,000 IU orally daily for 30 days, the control group being given a placebo (starch) during the same time period. Participants and researchers will be blinded regarding the ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Health workers in areas of care for patients with COVI-19
- • Adults
- • Men and women.
- • That they agree to participate in the study by signing the letter of informed consent
- Exclusion Criteria:
- • Those who know that they have already suffered from COVID-19
- • Those who have received a vitamin D supplement in the previous two weeks.
- • Difficulty obtaining blood samples
About Coordinación De Investigación En Salud, Mexico
Coordinación de Investigación en Salud, Mexico, is a leading clinical trial sponsor dedicated to advancing medical research and enhancing public health outcomes. With a robust infrastructure and a commitment to ethical standards, the organization collaborates with a network of healthcare professionals and institutions to conduct innovative clinical studies across various therapeutic areas. By leveraging cutting-edge methodologies and adhering to rigorous regulatory guidelines, Coordinación de Investigación en Salud aims to generate high-quality evidence that informs clinical practices and contributes to the development of safe and effective treatments for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mexico City, Distrito Federal, Mexico
Patients applied
Trial Officials
Miguel Angel Villasis-Keever
Principal Investigator
Coordinación de Investigación en Salud, Mexico
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials